Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab

ABSTRACTBooster vaccinations against SARS-CoV-2 are recommended 6–12 months after the last dose or infection in elderly and high-risk groups. The present analysis aims to evaluate whether an interval shorter than 12 months is required in multiple sclerosis patients receiving ofatumumab. Neutralizing...

Full description

Bibliographic Details
Main Authors: Tjalf Ziemssen, Marie Groth, Benjamin Ettle, Tobias Bopp
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
COVID19 vaccination
relapsing multiple sclerosis
ofatumumab
neutralizing antibodies
T-cell responses
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2316422

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2316422

Similar Items